Discover our new oral solid dose (OSD) development capabilities at our Bend, Oregon site.
Thermo Fisher Scientific’s Accelerator™ Drug Development 360° CDMO and CRO solutions offer a unique approach, currently unmatched by other third-party providers. By seamlessly connecting our global CDMO and CRO service and sites, we make drug development more efficient and effective—ultimately accelerating time to market for innovative therapies.
In a new video, Jennifer Cannon, president of commercial operations, pharma services at Thermo Fisher Scientific, highlights this advantage and references our Preclarus™ Digital Dashboard, which directly links clinical supply sites to patient enrollment sites—providing substantial benefits to biotech and biopharma customers. Watch the video to learn more.
See more: